Historical review from 2026-09-22. Current price and availability are unconfirmed; check the original marketplace.
PharmaCare generates $383/mo revenue with exceptional 92% profit margins, yielding a 2.1x annual profit multiple—attractive valuation territory. However, the business is under 1 year old with no listing date disclosed, and at sub-$400/mo revenue the absolute scale is early-stage; buyer should verify customer count, churn, and revenue trajectory to confirm sustainability beyond the founding period.
At $383/mo revenue from an undisclosed number of customers in a pre-product-market-fit timeframe, the business traction being purchased is minimal. A solo founder using AI coding tools (Claude, Cursor, or similar), open-source dental scheduling libraries, Stripe for billing, and managed hosting (AWS/Railway) could replicate core MVP dental practice management functionality—patient records, appointment scheduling, basic billing integration—in 10–12 weeks for $8K–$16K in direct costs. The asking price of $8,980 purchases mostly code that is neither proprietary nor differentiated; the real risk is customer acquisition and retention in a competitive vertical. Without verified customer count, churn data, or evidence of organic demand, building a comparable tool with a validated customer acquisition channel would likely be lower-risk and offer better margin control than buying an early-stage project with no demonstrated product-market fit. The high reported profit margin reflects low scale, not operational excellence.
Cash estimate includes the AI tools, APIs and infrastructure needed for a solo founder to recreate the software. Build time is informational and lightly weighted. The verdict is driven mainly by customers, users, verified earnings, retention, distribution, brand, data and operating history.
Pharmacare is a cloud-based dental practice management SaaS for clinics, covering patients, dental charts, appointments, billing, stock and reports.
Opens the original listing on Flippa
Get new listings with asking prices, monthly profit, deal scores, and key risks.
The best reviewed deals, concise and evidence-first. Unsubscribe anytime.
Preliminary screening based on marketplace and public data. Verify all financial, legal, technical, customer, and operational claims independently before making an acquisition decision. This is not financial or legal advice.